Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Total Debt

Short-term and long-term borrowings combined.

Amarin Corporation plcNASDAQ: AMRN

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 29.7% from a year ago

Total debt stood at $5.59M at the end of Q1 FY2026, down 29.7% from a year earlier and down 54.1% from the prior quarter. Over 3 fiscal years it compounded at +6.7% a year.

Context

  • Total debt amounted to 0.9% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -29.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.59M-54.1% QoQ
Last fiscal yearDec 2025
$12.16M+57.5% YoY
Year agoMar 2025
$7.94M-29.7% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.7%——
1 year+57.5%——
3-year CAGR+6.7%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
12.16M USD
Year-over-year change
+57.5%
4-year CAGR
+9.1%

Total Debt vs competitors

How AMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -29.7% is the 9th highest of 11, against a peer median of -9.8%.
  • Total debt amounts to 0.9% of total assets for AMRN, versus a peer median of 4.6%.
AMRN Competitors
Total Debt for AMRN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLLSCellectis S.A.Mar 2026$108.6M USD+18.3%+16.5%37.6%
LYELLyell Immunopharma, Inc.Mar 2026$48.85M USD-14.4%-9.0%13.9%
KRROKorro Bio, Inc.Mar 2026$42.89M USD-5.1%-36.1%23.4%
ALTAltimmune, Inc.Mar 2026$35.85M USD+2158.8%+216.7%10.7%
DBVTDBV Technologies S.A.Mar 2026$16.3M USD+32.0%+73.5%6.1%
ENGNenGene Holdings Inc.Apr 2026$8.25M USD-67.5%-0.3%2.7%
ANROAlto Neuroscience, Inc.Mar 2026$5.69M USD-78.5%-62.3%2.1%
AMRNAmarin Corporation plcMar 2026$5.59M USD-29.7%+6.7%0.9%
ACIUAC Immune S.A.Mar 2026CHF 4.3M CHF-16.8%+17.5%3.1%
LRMRLarimar Therapeutics, Inc.Mar 2026$3.78M USD-22.3%-9.1%1.8%
SLNSilence Therapeutics plcMar 2026$136K USD+126.7%-28.9%0.1%
Peer median (excluding AMRN) —-9.8%-4.7%4.6%

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents219.45M217.67M199.25M121.04M134.86M
Short-term Investments234.67M91.7M121.41M173.18M167.93M
Net Receivables163.65M130.99M133.56M122.28M126.83M
Inventory234.68M228.73M258.62M166.05M195.91M
Other Current Assets3.92M20.02M525K12.85M24.35M
Total Current Assets878.73M689.1M724.98M595.4M649.88M
Property, Plant & Equipment (Net)9.09M9.95M8.42M7.61M6.47M
Goodwill000013.36M
Intangible Assets23.55M21.78M19.3M16.39M0
Long-term Investments35M1.28M000
Tax Assets00000
Other Non-current Assets121.71M164.08M78.98M65.95M1.06M
Total Non-current Assets189.34M197.08M106.7M89.95M20.89M
Total Assets1.07B886.18M831.68M685.35M670.77M
Account Payables114.92M64.6M52.76M40.37M45.35M
Short-term Debt00000
Tax Payables00000
Deferred Revenue2.65M2.2M2.34M00
Other Current Liabilities45.6M35.64M185.23M17.55M149.1M
Total Current Liabilities370.68M259.48M259.28M179.95M194.46M
Long-term Debt00006.08M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)14.06M13.15M2.51M00
Other Non-current Liabilities7.65M8.21M9.06M11.5M4.87M
Total Non-current Liabilities30.28M31.37M20.31M19.22M17.03M
Total Liabilities400.97M290.85M279.59M199.17M211.49M
Common Stock294.03M299M302.76M305.3M310.18M
Retained Earnings(1.42B)(1.53B)(1.59B)(1.67B)(1.71B)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity667.1M595.33M552.1M486.18M459.28M
Total Debt8.58M10.02M8.74M7.72M12.16M
Net Debt(210.88M)(207.65M)(190.52M)(113.32M)(122.7M)

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.